Meeting
2018 ASCO Annual Meeting
TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models.
Authors
Jie Yu
Takeda Pharmaceuticals, Cambridge, MA
Jie Yu , Jessica Huck Sappal , Mengkun Zhang , Karuppiah Kannan , Jonathan Zalevsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Pharmacology
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2567)
DOI
10.1200/JCO.2018.36.15_suppl.2567
Abstract #
2567
Poster Bd #
393
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin (cis)-ineligible.
First Author: Petros Grivas
Poster
2019 ASCO Annual Meeting
A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma.
First Author: Nizar M. Tannir
Poster
2019 ASCO Annual Meeting
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.
First Author: Michael E. Hurwitz
Poster
2019 Genitourinary Cancers Symposium
Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial.
First Author: Jonathan Alexander Chatzkel